WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). The EC decision follows the positive opinion received from the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) in June 2021 recommending the conditional marketing authorization of Minjuvi.
People living with relapsed or refractory DLBCL in the EU, have historically had limited treatment options and a poor prognosis. However, with the ECs approval of Minjuvi, eligible patients now have a new and much needed treatment option, said Herv Hoppenot, Chief Executive Officer, Incyte. We will now focus our efforts on working with individual countries in Europe to provide people access to this new treatment.
The approval of Minjuvi is a crucial milestone for patients with relapsed or refractory DLBCL in Europe, said Jean-Paul Kress, M.D., Chief Executive Officer, MorphoSys. DLBCL is the most common type of non-Hodgkin lymphoma in adults and Minjuvi addresses an urgent unmet medical need for the 30-40% of people who do not respond to or relapse, after initial therapy.
The conditional approval is based on the results from the L-MIND study evaluating the safety and efficacy of Minjuvi in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT). The results showed best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%, as assessed by an independent review committee. The median duration of response (mDOR) was 43.9 months after a minimum follow up of 35 months (secondary endpoint). Minjuvi together with lenalidomide was shown to provide a clinically meaningful response and the side effects were manageable. Warnings and precautions for Minjuvi include infusion-related reactions, myelosuppression, including neutropenia and thrombocytopenia, infections and tumour lysis syndrome.
The data from the L-MIND study demonstrate the potential benefits, including long duration of response, that tafasitamab may have for eligible DLBCL patients, said Professor Pier Luigi Zinzani M.D., Ph.D., Head of the Lymphoma Group at University of Bologna. It is encouraging to see new treatments become available for these patients, especially given the historical lack of treatment options in this area.
Incyte and MorphoSys share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the United States. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and is marketed by Incyte under the brand name Minjuvi in the EU.
About Diffuse Large B-Cell LymphomaDLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide, comprising 40% of all cases4, and is characterized by rapidly growing masses of malignant B-cells in the lymph nodes, spleen, liver, bone marrow or other organs5. It is an aggressive disease with about one in three patients not responding to initial therapy or relapsing thereafter6. In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL7,8,9.
About L-MINDThe L-MIND trial is a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had at least one, but no more than three prior lines of therapy, including an anti-CD20 targeting therapy (e.g., rituximab), who are not eligible for high-dose chemotherapy (HDC) or autologous stem cell transplant (ASCT). The studys primary endpoint is overall response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). The study reached its primary completion in May 2019.
For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085.
About Minjuvi (tafasitamab)Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
In the United States, Monjuvi (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
In Europe, Minjuvi (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.
Minjuvi and Monjuvi are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and marketed by Incyte under the brand name Minjuvi in the EU.
XmAb is a registered trademark of Xencor, Inc.
Safety Information from the EU Summary of Product Characteristics (SmPC)Infusion-related reactions may occur and have been reported more frequently during the first infusion. Patients should be monitored closely throughout the infusion and should be advised to contact their healthcare professionals if they experience signs and symptoms of infusion related reactions including fever, chills, rash or breathing problems within 24 hours of infusion. A premedication should be administered to patients prior to starting tafasitamab infusion. Based on the severity of the infusion-related reaction, tafasitamab infusion should be interrupted or discontinued and appropriate medical management should be instituted.
Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with Minjuvi.
Minjuvi should be administered to patients with an active infection only if the infection is treated appropriately and well controlled. Patients with a history of recurring or chronic infections may be at increased risk of infection and should be monitored appropriately. Patients should be advised to contact their healthcare professionals if fever or other evidence of potential infection, such as chills, cough or pain on urination, develops.
Treatment with Minjuvi in combination with lenalidomide should not be initiated in female patients unless pregnancy has been excluded.
The most common adverse reactions were infections, neutropenia, asthenia, anemia, diarrhea, thrombocytopenia, cough, oedema peripheral, pyrexia and decreased appetite.
Minjuvi may cause serious adverse reactions. The most common serious adverse reactions were infection, including pneumonia and febrile neutropenia.
Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia, thrombocytopenia and anemia. Complete blood counts should be monitored throughout treatment and prior to administration of each treatment cycle.
About IncyteIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya (guselkumab) developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis became the first drug based on MorphoSys antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the companys proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit http://www.morphosys.com or http://www.morphosys-us.com.
Tremfya is a registered trademark of Janssen Biotech, Inc.
Incyte Forward-looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Companys expectations relating to the use of tafasitamab for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the Companys ongoing clinical development program for tafasitamab, and its DLBCL program generally, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Companys clinical trials, supply chain, and other third-party providers and development and discovery operations; determinations made by the European Commission and other regulatory authorities; the Companys dependence on its relationships with its collaboration partners; the efficacy or safety of the Companys products and the products of the Companys collaboration partners; the acceptance of the Companys products and the products of the Companys collaboration partners in the marketplace; market competition; sales, marketing, manufacturing, and distribution requirements; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
MorphoSys Forward-looking StatementsThis communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
_____________________1 DRG Epidemiology data.2 Kantar Market Research (TPP testing 2018).3 Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.4 Cancer Research UK. Diffuse large B cell lymphoma. Available at https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma. Accessed: May 2021.5 Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:20916. doi.org/10.1016/j.beha.2018.07.014.6 Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253265. doi.org/10.3747/co.26.5421.7 DRG Epidemiology data.8 Kantar Market Research (TPP testing 2018).9 Friedberg, Jonathan W. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182/asheducation-2011.1.498.
Originally posted here:
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults...
- Bone Marrow and Stem Cell Transplants - Christiana Care ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cell Doctors, Physician Team, Our Doctors [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- California Stem Cell Report: California Stem Cell Agency ... [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Stem Cell Companies - A Comprehensive Overview [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Core mechanism for root growth identified [Last Updated On: August 25th, 2014] [Originally Added On: August 25th, 2014]
- Delaware Stem Cell Treatment | Stem Cell Treatments [Last Updated On: September 9th, 2014] [Originally Added On: September 9th, 2014]
- Can a bodys own stem cells help heal a heart? [Last Updated On: October 19th, 2014] [Originally Added On: October 19th, 2014]
- The California Cloning and Stem Cell Laws [Last Updated On: December 27th, 2014] [Originally Added On: December 27th, 2014]
- IPS Stem Cells: New Ethical Quandaries - Santa Clara ... [Last Updated On: December 27th, 2014] [Originally Added On: December 27th, 2014]
- Stem-cell battles: Stem-cell research in the USA is facing ... [Last Updated On: April 9th, 2015] [Originally Added On: April 9th, 2015]
- DSU AgDiscovery 2015 - Investing in the Future of American ... [Last Updated On: June 1st, 2015] [Originally Added On: June 1st, 2015]
- De-Differentiation of Somatic Cells to a Pluripotent State ... [Last Updated On: June 29th, 2015] [Originally Added On: June 29th, 2015]
- Alpine Rose Leaf Extract for Environmental Protection for ... [Last Updated On: October 1st, 2015] [Originally Added On: October 1st, 2015]
- Efficient Differentiation of Mouse Embryonic Stem Cells ... [Last Updated On: October 1st, 2015] [Originally Added On: October 1st, 2015]
- Stem Cells - Eppendorf [Last Updated On: October 2nd, 2015] [Originally Added On: October 2nd, 2015]
- Home | www.papoutsakis.org [Last Updated On: October 4th, 2015] [Originally Added On: October 4th, 2015]
- University of Delaware Chemical Engineering [Last Updated On: October 31st, 2015] [Originally Added On: October 31st, 2015]
- Delaware (Stem Cell) - what-when-how [Last Updated On: November 3rd, 2016] [Originally Added On: November 3rd, 2016]
- Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient - Detroit Free Press [Last Updated On: March 11th, 2017] [Originally Added On: March 11th, 2017]
- Lions LB Paul Worrilow Making A Difference On And Off The Field - FanRag Sports (blog) [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- Detroit Lions' Paul Worrilow has beaten odds, inspires others to help - Detroit Free Press [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Delaware First Media [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Regenerative Cell Therapy - Delaware Integrative Medicine [Last Updated On: June 22nd, 2018] [Originally Added On: June 22nd, 2018]
- Stem Cell Doctors Delaware, Stem cell injections, Stem ... [Last Updated On: October 14th, 2018] [Originally Added On: October 14th, 2018]
- Stem Cell Therapy | Regenerative Delaware [Last Updated On: February 22nd, 2019] [Originally Added On: February 22nd, 2019]
- Regenerative Cell Treatment &Therapy - Delaware ... [Last Updated On: February 22nd, 2019] [Originally Added On: February 22nd, 2019]
- Stem Cell therapy Wilmington Delaware 19810 [Last Updated On: February 27th, 2019] [Originally Added On: February 27th, 2019]
- Stem Cell therapy Newark Delaware 19725 [Last Updated On: February 27th, 2019] [Originally Added On: February 27th, 2019]
- SignalRx [Last Updated On: March 22nd, 2019] [Originally Added On: March 22nd, 2019]
- Westfield High School Principal Derrick Nelson was 'gift ... [Last Updated On: May 16th, 2019] [Originally Added On: May 16th, 2019]
- Stem Cell therapy Lewes Delaware 19958 [Last Updated On: September 14th, 2019] [Originally Added On: September 14th, 2019]
- Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? - The Altcoin Mercury [Last Updated On: September 25th, 2019] [Originally Added On: September 25th, 2019]
- What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts - The Lamp News [Last Updated On: October 26th, 2019] [Originally Added On: October 26th, 2019]
- From inspiration to innovation | UDaily - UDaily [Last Updated On: November 14th, 2019] [Originally Added On: November 14th, 2019]
- Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects - Technology Magazine [Last Updated On: December 17th, 2019] [Originally Added On: December 17th, 2019]
- Gore, Mayo Clinic team up to deliver breakthrough medical therapies - Plastics Today [Last Updated On: December 17th, 2019] [Originally Added On: December 17th, 2019]
- First CAR-T cell cancer therapy patient in Delaware - Dover Post [Last Updated On: February 10th, 2020] [Originally Added On: February 10th, 2020]
- Stem Cell therapy Middletown Delaware 19709 [Last Updated On: February 10th, 2020] [Originally Added On: February 10th, 2020]
- Data from Incytes Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings - Yahoo Finance [Last Updated On: May 20th, 2020] [Originally Added On: May 20th, 2020]
- 'Billion Dollar Burger' Asks: What Is Meat? - Delaware First Media [Last Updated On: June 17th, 2020] [Originally Added On: June 17th, 2020]
- Bone Marrow and Stem Cell Transplants ChristianaCare [Last Updated On: June 20th, 2020] [Originally Added On: June 20th, 2020]
- Rock snot discovered in another Pennsylvania waterway - pennlive.com [Last Updated On: September 12th, 2020] [Originally Added On: September 12th, 2020]
- MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of... [Last Updated On: August 31st, 2021] [Originally Added On: August 31st, 2021]
- Why Eraser Enzymes Go Wrong and Lead to Cancer - SciTechDaily [Last Updated On: December 10th, 2021] [Originally Added On: December 10th, 2021]
- Microscopy Devices Market Competitive Insights and Precise Outlook 2021-2028 Industrial IT - Industrial IT [Last Updated On: June 4th, 2022] [Originally Added On: June 4th, 2022]
- Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027 - BioSpace [Last Updated On: June 4th, 2022] [Originally Added On: June 4th, 2022]
- Transplant Diagnostic Market: Increase in Number of Cancer & Blood Disorder Patients to Drive the Market - BioSpace [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- Antibody Therapy Market Propels at a Robust CAGR of 13.2% due to Rising Cancer and Other Chronic Disease Prevalence Future Market Insights, Inc. -... [Last Updated On: July 19th, 2022] [Originally Added On: July 19th, 2022]
- Immunoglobin Products Market to Witness Comprehensive Growth by 2031 - BioSpace [Last Updated On: July 19th, 2022] [Originally Added On: July 19th, 2022]
- Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years - BioSpace [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 - BioSpace [Last Updated On: July 27th, 2022] [Originally Added On: July 27th, 2022]
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News [Last Updated On: August 5th, 2022] [Originally Added On: August 5th, 2022]
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 - BioSpace [Last Updated On: August 14th, 2022] [Originally Added On: August 14th, 2022]
- Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 - BioSpace [Last Updated On: August 14th, 2022] [Originally Added On: August 14th, 2022]
- Regenerative Therapies Market 2018 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2026 - Digital Journal [Last Updated On: August 22nd, 2022] [Originally Added On: August 22nd, 2022]
- Cell Banking Outsourcing Market is Driven by Rising Number of Stem Cell Therapies across the Globe - BioSpace [Last Updated On: September 8th, 2022] [Originally Added On: September 8th, 2022]
- Virology Market Growth Prospects, Trends and Forecast up to 2030 - BioSpace [Last Updated On: September 8th, 2022] [Originally Added On: September 8th, 2022]
- DiMethyl Sulfoxide (DMSO) Market to Touch US$ 838.6 Million in 2032 Owing to its Widespread Application in End-Use Industries & Anti-Inflammatory... [Last Updated On: September 16th, 2022] [Originally Added On: September 16th, 2022]
- External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market - BioSpace [Last Updated On: September 16th, 2022] [Originally Added On: September 16th, 2022]
- Stem Cells Market is Expected to Grow with High Probability Business Opportunity by 2028 - Digital Journal [Last Updated On: October 4th, 2022] [Originally Added On: October 4th, 2022]
- Orthobiologics Market to Receive Overwhelming Hike in Revenues by 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- PRP and PRF in Cosmetics Market Growth Opportunities Analysis Report - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Mice Model Technologies Market Outlook, Competitive Landscape and Forecasts to 2031 - openPR [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]
- Japan Stem Cells Market to be at Forefront by 2028 [Last Updated On: November 24th, 2022] [Originally Added On: November 24th, 2022]